Millipore Sigma Vibrant Logo

566313 SIRT1 Activator II - CAS 374922-43-7 - Calbiochem

概述

Replacement Information

重要规格表

CAS #Empirical Formula
374922-43-7C₂₂H₁₅FN₄O₂S

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
566313-10MGCN
正在查询供货情况......
目前缺货
目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余:另行通知
      其余:另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      玻璃瓶 10 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      Request Pricing
      Description
      OverviewA cell-permeable pyrroloquinoxaline compound that acts as a reversible SIRT1 activator (10 µM causes ~2.3-fold fluorescent enhancement in a fluorescent assay using hrSIRT1) and enhances fat mobilization in fully differentiated 3T3L1 fibroblasts. Shown to inhibit LPS-induced TNF-α release in THP-1 cells by ~10-fold more potent than resveratrol (Cat. No. 554325).
      Catalogue Number566313
      Brand Family Calbiochem®
      Synonyms3-(Benzenesulfonyl)-1-(4-fluorophenyl)pyrrolo[4,5-b]quinoxalin-2-amine , CAY10602, SIRT1 Activator II
      References
      ReferencesLavu, S., et al. 2008. Nat. Rev. Drug Discov. 7, 841.
      Nayagam, V.M., et al. 2006. J. Biomol. Screen. 11, 959.
      Product Information
      CAS number374922-43-7
      FormOff-white powder
      Hill FormulaC₂₂H₁₅FN₄O₂S
      Chemical formulaC₂₂H₁₅FN₄O₂S
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      566313-10MGCN 04055977191363

      Documentation

      SIRT1 Activator II - CAS 374922-43-7 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      SIRT1 Activator II - CAS 374922-43-7 - Calbiochem 分析证书

      标题批号
      566313

      参考

      参考信息概述
      Lavu, S., et al. 2008. Nat. Rev. Drug Discov. 7, 841.
      Nayagam, V.M., et al. 2006. J. Biomol. Screen. 11, 959.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-November-2021 JSW
      Synonyms3-(Benzenesulfonyl)-1-(4-fluorophenyl)pyrrolo[4,5-b]quinoxalin-2-amine , CAY10602, SIRT1 Activator II
      DescriptionA cell-permeable pyrroloquinoxaline compound that acts as a reversible SIRT1 activator (10 µM causes ~2.3-fold fluorescent enhancement in a fluorescent assay using hrSIRT1) and enhances fat mobilization in fully differentiated 3T3L1 fibroblasts. Shown to inhibit LPS-induced TNF-α release in THP-1 cells by ~10-fold more potent than resveratrol (Cat. No. 554325).
      FormOff-white powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number374922-43-7
      Chemical formulaC₂₂H₁₅FN₄O₂S
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLavu, S., et al. 2008. Nat. Rev. Drug Discov. 7, 841.
      Nayagam, V.M., et al. 2006. J. Biomol. Screen. 11, 959.